Immune effect and prognosis of transcatheter arterial chemoembolization and tyrosine kinase inhibitors therapy in patients with hepatocellular carcinoma

Figure 3 Progression free survival and overall survival curves of the patient. A: There was no significant difference in progression free survival time among different combination therapy groups; B: There was no significant difference in overall survival time among different combination therapy groups. T + A: Transcatheter arterial chemoembolization combined with apatinib group; T + L: Transcatheter arterial chemoembolization combined with lenvatinib group; T + S: Transcatheter arterial chemoembolization combined with sorafenib group; T + D: Transcatheter arterial chemoembolization combined with donafenib group.